The short version
- Why people research itRecovery after severe brain injury and for levodopa-induced dyskinesia in Parkinson's disease.
- What the evidence isTwo randomized placebo-controlled trials, both positive and both qualified.
- What to watchVisual hallucinations, which affected roughly one in four people in the dyskinesia trial.
How Amantadine works
Mechanism is layered, which is why one explanation does not hold. It weakly antagonizes NMDA receptors and raises dopamine synthesis and release, and in culture it also reduced microglial inflammatory release and induced GDNF in astroglia, which protected dopamine neurons (Ossola 2011).
It is a weak, non-competitive antagonist of the NMDA glutamate receptor, it increases dopamine synthesis and release in the striatum, and in cell culture it reduced activation of microglia and induced the neurotrophin GDNF in astroglia, which protected dopamine neurons from toxins. Rats treated with it for a few days showed enhanced dopamine-receptor coupling to G proteins that disappeared with longer treatment, a hint of how quickly the system adapts. It was first used against influenza A, then found by accident to help Parkinson's symptoms, and is now mainly used for levodopa-induced dyskinesia and for slow recovery after severe brain injury.
- Oral
On the goal map: Catecholamine & dopaminergic drive (Focus, memory & cognition)
Research on Amantadine4 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Human (randomized placebo-controlled trials in severe traumatic brain injury and in levodopa-induced dyskinesia; FDA-approved extended-release products).
Human clinical evidence
Two randomized placebo-controlled trials, both positive and both qualified. In 184 patients in a vegetative or minimally conscious state after traumatic brain injury, recovery on the Disability Rating Scale was significantly faster during four weeks of amantadine, but the improvement slowed after stopping and the overall change at week 6 was similar between groups (Giacino 2012). In 126 people with Parkinson's disease and levodopa-induced dyskinesia, an extended-release capsule improved dyskinesia scores significantly versus placebo and shortened OFF time, with visual hallucinations, peripheral edema and dizziness more common and discontinuations for adverse events about three times as frequent (Pahwa 2017).
Correlative data
Decades of clinical use. Amantadine has been prescribed since the 1960s, first for influenza A and then for Parkinson's disease, and is recommended in brain-injury guidelines (Dekundy 2024). Its use for fatigue and as an off-label stimulant in healthy people is anecdotal and is not supported by a trial in that group.
How the mechanism reads
Mechanism is layered, which is why one explanation does not hold. It weakly antagonizes NMDA receptors and raises dopamine synthesis and release, and in culture it also reduced microglial inflammatory release and induced GDNF in astroglia, which protected dopamine neurons (Ossola 2011). In rats a few days of treatment enhanced dopamine-receptor coupling that vanished on longer treatment (Peeters 2002), a reminder that adaptation is part of the picture.
Experimental, animal or cellThe predicted downside is the one the trials found. Dopamine enhancement and NMDA blockade predict hallucinations, vivid dreams, insomnia and swelling in the legs; renal clearance predicts accumulation in kidney impairment; and a drug that lowers the seizure threshold in some people is a reason for caution with epilepsy.
Mechanistic
Amantadine safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Reduced kidney function, since it is cleared by the kidney and accumulates.
- Epilepsy or a seizure history, because it can lower the threshold.
- Heart rhythm problems, as it can prolong the QT interval in some people.
- Older adults prone to confusion or hallucinations, which were common in the trial.
- Taking other dopaminergic or anticholinergic drugs without review.
What’s expected
- Vivid dreams, insomnia or restlessness, especially taken late.
- Ankle swelling and a mottled skin pattern on the legs with longer use.
Watch for
- Visual hallucinations, which affected roughly one in four people in the dyskinesia trial.
- Confusion or sudden agitation.
- Fainting or palpitations.
Labs that tell you it’s working
- Cystatin C with eGFR: the kidney sets how long the drug stays.
- Comprehensive Metabolic Panel: creatinine and electrolytes.
- Prolactin: dopamine release lowers it, a pharmacodynamic readout.
- Complete Blood Count: baseline before a long course.
Dopamine-releasing weak NMDA antagonist cleared by the kidney; the two randomized trials recorded hallucinations, edema and dizziness. PMID 22375973 PMID 28604926 PMID 21586298
Bloodwork to runHow you would know it is working: 6 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Amantadine FAQ4 common questions
- Is Amantadine approved for human use?
- Amantadine is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
- What is Amantadine researched for?
- Recovery after severe brain injury and for levodopa-induced dyskinesia in Parkinson's disease.
- Which labs show whether it's doing anything?
- Cystatin C with eGFR; Comprehensive Metabolic Panel; Prolactin; Complete Blood Count: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Amantadine: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



